Robert J. Bertoldi Appointed Interim Chief Executive Officer of WellGen, Inc.

NORTH BRUNSWICK, N.J., September 2, 2008 - WellGen, Inc. today announced that Robert J. Bertoldi has been appointed interim Chief Executive Officer.

Mr. Bertoldi will assume the position of CEO in addition to his role as President and Chief Financial Officer of Amphion Innovations plc (LSE: AMP). Amphion, a developer of medical and technology businesses, is a significant shareholder in WellGen. He succeeds Dr. Kathleen P. Mullinix.

Mr. Bertoldi stated, "I am pleased to take on this responsibility and want to thank Dr. Mullinix for her service over the past two years." Mr. Bertoldi was a founder, President, and CFO of Amphion Capital Partners LLC (Amphion Innovations’ predecessor company) and VennWorks LLC.

Mr. Bertoldi is also a general partner of Amphion Partners LLC (formerly known as Wolfensohn Partners, LP). Prior to that, he served as Chief Financial Officer for James D. Wolfensohn, Inc. and Hambro America Inc. He began his career at KPMG and left as a manager in the investment services department. Mr. Bertoldi received a B.A. in Accounting and Economics from Queens College, New York in 1976 and became a Certified Public Accountant in 1978. He is a member of the AICPA and NYSCPA.

About Amphion
Amphion Innovations (LSE: AMP) builds shareholder value in high growth companies in the medical and technology sectors, by using a focused, hands-on company building approach, based on decades of experience in both the US and UK. Amphion has significant shareholding in eight Partner Companies and two specialized entities, developing proven technologies targeting substantial commercial marketplaces, each in excess of $1 billion. Each Partner Company is chosen with the goal of achieving an exit valuation in excess of $100 million.

On the web:

About WellGen
WellGen, Inc., based in North Brunswick, NJ, is a biotechnology company that is discovering and developing products for the food, therapeutics, and dietary supplement markets. WellGen's proprietary technology platform is a method of screening the effects of food and related substances on the expression of genes associated with human health conditions. The company has developed proprietary substances that help maintain health and reduce risk and severity for a variety of diseases.

Please visit our website at for more information.